Meghana Trivedi
Meghana Trivedi
Unknown affiliation
Verified email at uh.edu
Title
Cited by
Cited by
Year
Metastasis dormancy in estrogen receptor–positive breast cancer
XHF Zhang, M Giuliano, MV Trivedi, R Schiff, CK Osborne
Clinical Cancer Research 19 (23), 6389-6397, 2013
1822013
Perspective on circulating tumor cell clusters: why it takes a village to metastasize
M Giuliano, A Shaikh, HC Lo, G Arpino, S De Placido, XH Zhang, ...
Cancer research 78 (4), 845-852, 2018
1012018
Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiopoietin-1 in type 2 diabetes
F Liu, DD Chen, X Sun, HH Xie, H Yuan, WP Jia, AF Chen
Diabetes 63 (5), 1763-1778, 2014
1002014
Biological mechanisms and clinical implications of endocrine resistance in breast cancer
M Giuliano, R Schiff, CK Osborne, MV Trivedi
The Breast 20, S42-S49, 2011
962011
Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications
M Giuliano, MV Trivedi, R Schiff
Breast Care 8 (4), 256-262, 2013
892013
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ...
Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016
872016
The changing role of ER in endocrine resistance
A Nardone, C De Angelis, MV Trivedi, CK Osborne, R Schiff
The Breast 24, S60-S66, 2015
772015
Evaluation of in vivo p-glycoprotein phenotyping probes
JD Ma, SM Tsunoda, JS Bertino, M Trivedi, KK Beale, AN Nafziger
Clinical pharmacokinetics 49 (4), 223-237, 2010
672010
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy
M Giuliano, H Hu, YC Wang, X Fu, A Nardone, S Herrera, S Mao, ...
Clinical Cancer Research 21 (17), 3995-4003, 2015
662015
Optimal use of G-CSF administration after hematopoietic SCT
M Trivedi, S Martinez, S Corringham, K Medley, ED Ball
Bone marrow transplantation 43 (12), 895-908, 2009
552009
Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats
M Trivedi, MF Lokhandwala
American Journal of Physiology-Renal Physiology 289 (2), F298-F304, 2005
522005
Oral glutamine in preventing treatment‐related mucositis in adult patients with cancer: a systematic review
C Sayles, SC Hickerson, RR Bhat, J Hall, KW Garey, MV Trivedi
Nutrition in Clinical Practice 31 (2), 171-179, 2016
492016
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis
M Giuliano, S Herrera, P Christiny, C Shaw, CJ Creighton, T Mitchell, ...
Breast cancer research 17 (1), 1-9, 2015
482015
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis
M Giuliano, S Herrera, P Christiny, C Shaw, CJ Creighton, T Mitchell, ...
Breast cancer research 17 (1), 1-9, 2015
482015
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer
M Trivedi, I Budihardjo, K Loureiro, TR Reid, JD Ma
Future Medicine Ltd 4 (4), 483-500, 2008
382008
Eribulin: a novel cytotoxic chemotherapy agent
JN Preston, MV Trivedi
Annals of Pharmacotherapy 46 (6), 802-811, 2012
302012
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance
L Malorni, M Giuliano, I Migliaccio, T Wang, CJ Creighton, M Lupien, X Fu, ...
Molecular Cancer Research 14 (5), 470-481, 2016
292016
Dopamine recruits D1A receptors to Na-K-ATPase-rich caveolar plasma membranes in rat renal proximal tubules
M Trivedi, VA Narkar, T Hussain, MF Lokhandwala
American Journal of Physiology-Renal Physiology 287 (5), F921-F931, 2004
282004
Rosiglitazone Restores G-Protein Coupling, Recruitment, and Function of Renal Dopamine D1A Receptor in Obese Zucker Rats
M Trivedi, A Marwaha, M Lokhandwala
Hypertension 43 (2), 376-382, 2004
272004
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
A Nardone, H Weir, O Delpuech, H Brown, C De Angelis, ML Cataldo, ...
British journal of cancer 120 (3), 331-339, 2019
252019
The system can't perform the operation now. Try again later.
Articles 1–20